Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, open clinical study, which was designed to evaluate the
efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal
injection in the treatment of patients with NSCLC associated with leptomeningeal metastases.